Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD
ASCENTRA-CD expected to enroll approximately 60 patients with moderate to severe Crohn’s disease
ASCENTRA-CD expected to enroll approximately 60 patients with moderate to severe Crohn’s disease